HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO HighTide Therapeutics - Its Outlook in NASH Field Is Not Optimistic, with High Risks

Pre-IPO Mirxes Holding Company - The Profit Model in the Post Pandemic Era Needs to Be Verified

China Healthcare Weekly (Aug.18) - TCM Formula Granules VBP, Global Financing Rebound, CR Sanjiu

Wuxi Biologics (2269.HK) - Investor Day Brings New Surprises

Akeso Biopharma (9926.HK) - Behind the Deal with Summit: A Snake Swallows an Elephant?

China Biotech – The Commercialization Performance and The Outlook

Wuxi Biologics (2269.HK) - Some New Business Updates and the Outlook

WuXi AppTec (2359.HK/603259.CH) 2023Q1 - The Signals Behind the Plunge in Stock Price

Equity Capital Markets

Wuhan YZY Biopharma / Equity Capital Markets

<ul>
<li>YZY is a company that is serious about drug development However, there is actually high R&amp;D risk of its pipeline candidates. So, YZY’s R&amp;D capability has yet to be proven.</li>
<li>There are still many unanswered questions in the whole direction of bispecific antibody. If YZY’s candidates fail to prove better marginal clinical benefits, they won’t have good commercialization performance. </li>
<li>YZY has a long way to go based on its pipeline situation. Considering <a href="https://www.smartkarma.com/entities/wuhan-yzy-biopharma-co-ltd" target="_blank" data-smartkarma-citation="entities:36600:1" rel="noopener">Wuhan YZY Biopharma (YZY HK)</a> has no product in commercialization stage, its valuation may not be high.</li>
</ul>


YZY is a company that is serious about drug development However, there is actually high R&amp;D risk of its pipeline candidates. So, YZY’s R&amp;D capability has yet to be proven.
There are still many unanswered questions in the whole direction of bispecific antibody. If YZY’s candidates fail to prove better marginal clinical benefits, they won’t have good commercialization performance. 
YZY has a long way to go based on its pipeline situation. Considering Wuhan YZY Biopharma (YZY HK) has no product in commercialization stage, its valuation may not be high.


Beijing Wantai Biological Phar (603392 CH)

Pre-IPO Wuhan YZY Biopharma - Both R&D and Commercialization Capabilities Have yet to Be Proven